A phase II trial of recombinant protective antigen anthrax vaccine [SparVax] for the prevention of inhaled anthrax.

Trial Profile

A phase II trial of recombinant protective antigen anthrax vaccine [SparVax] for the prevention of inhaled anthrax.

Suspended
Phase of Trial: Phase II

Latest Information Update: 16 Dec 2013

At a glance

  • Drugs Recombinant protective antigen anthrax vaccine Altimmune (Primary)
  • Indications Anthrax
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 16 Dec 2013 Status changed from planning to suspended, according to a PharmAthene media release. PharmAthene will receive a letter providing details of the basis for the second clinical hold, within 30 days.
    • 01 Aug 2013 Planned initiation date changed from 1 Dec 2012 to 1 Dec 2013, based on information in a PharmAthene media release. The trial is planned to begin during 2013.
    • 30 May 2013 Status changed from suspended to planning, according to a PharmAthene media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top